Teva Announces Launch of $2,000,000,000 (Equivalent) Offering of Senior Notes

Core Viewpoint - Teva Pharmaceutical Industries Ltd. plans to issue $2 billion in senior notes through its finance subsidiaries to fund tender offers for existing senior notes and manage outstanding debt [1][2]. Group 1: Offering Details - Teva intends to offer EUR-denominated Senior Notes and USD-denominated Senior Notes through its special purpose finance subsidiaries [1]. - The maximum combined aggregate purchase price for the tender offers is up to$2 billion, excluding accrued and unpaid interest [2]. - The Notes will be unsecured senior obligations of the Issuers and will be unconditionally guaranteed on a senior basis by Teva [3]. Group 2: Use of Proceeds - The net proceeds from the offerings will be used to fund tender offers for specific senior notes maturing in 2026, 2027, 2029, and 2031 [2]. - Remaining proceeds may be used for the repayment of outstanding debt upon maturity, tender offer, or earlier redemption [2]. Group 3: Regulatory Information - The offering will be made pursuant to an effective automatic shelf registration statement filed with the SEC [4]. - The offering will be conducted only by means of a prospectus supplement and accompanying base prospectus [4].